Home Special Topics Technology Offerings Content

Athero-Blocker - New peptides for the prevention and treatment of atherosclerosis

next article

14.05.2008

Scientists at the RWTH Aachen have identified new peptides which can be used for the prevention of atherosclerosis or in the treatment of related cardiovascular diseases. It is known that adherent activated platelets secrete chemoattractants, such as the chemokines PF4 and RANTES, which are responsible for monocyterecruitment. Receptor-blocking experiments and studies with knock-out mice indicated that RANTES signals contribute to intimal hyperplasia and macrophage infiltration in models of restenosis. Moreover, it plays an important role in the initiation and maintenance of atherosclerosis. Athero-Blocker is specifically targeting the interaction between the chemokines RANTES and PF4. It can thereby abrogate the proatherogenic enhancement of monocyte recruitment caused by this interaction. A good efficacy of Athero-Blocker has been demonstrated in in vitro experiments, in cell based test systems and in mouse models in vivo.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

info@technologieallianz.de | Source: TechnologieAllianz e.V.
Further information: www.technologieallianz.de/angebote.php?sort=sag&id=0675&lang=en
www.technologieallianz.de

next article